Table 1. Patient characteristics . . N .... | American Society of Hematology

Table 1.

Patient characteristics

		N	%
Age at ICI initiation	Median age	40.1 y
	<50	48	69.6
	50-59.9	7	10.1
	60-69.9	6	8.7
	70-79.9	5	7.2
	≥80	3	4.3
Sex	Female	33	47.8
	Male	36	52.2
Histology	Nodular sclerosing	59	85.5
	Mixed cellularity	3	4.3
	Classical NOS	6	8.7
	Lymphocyte rich	1	1.4
Bulky	Yes	21	30.4
	No	47	68.1
	Unknown	1	1.4
Extranodal disease	Yes	29	42.0
	No	40	58.0
Stage at diagnosis	I	2	2.9
	II	23	33.3
	III	15	21.7
	IV	29	42.0
Pre-ICI disease	Relapsed	36	52.2
	Refractory	17	24.6
	First diagnosis	16	23.2
Previous ASCT	Yes	50	72.5
	No	19	27.5
Previous radiation	Yes	30	43.5
	No	39	56.5
ICIs used	Nivolumab	54	78.3
	Pembrolizumab	12	17.4
	Other	3	4.3
Number of disease sites at ICI initiation	≤5 sites	45	65.2
	>5 sites	24	34.8
Number of therapies before ICIs	Mean	4.4 therapies
	Q1, Q3	1, 6
	Range	0-16

		N	%
Age at ICI initiation	Median age	40.1 y
	<50	48	69.6
	50-59.9	7	10.1
	60-69.9	6	8.7
	70-79.9	5	7.2
	≥80	3	4.3
Sex	Female	33	47.8
	Male	36	52.2
Histology	Nodular sclerosing	59	85.5
	Mixed cellularity	3	4.3
	Classical NOS	6	8.7
	Lymphocyte rich	1	1.4
Bulky	Yes	21	30.4
	No	47	68.1
	Unknown	1	1.4
Extranodal disease	Yes	29	42.0
	No	40	58.0
Stage at diagnosis	I	2	2.9
	II	23	33.3
	III	15	21.7
	IV	29	42.0
Pre-ICI disease	Relapsed	36	52.2
	Refractory	17	24.6
	First diagnosis	16	23.2
Previous ASCT	Yes	50	72.5
	No	19	27.5
Previous radiation	Yes	30	43.5
	No	39	56.5
ICIs used	Nivolumab	54	78.3
	Pembrolizumab	12	17.4
	Other	3	4.3
Number of disease sites at ICI initiation	≤5 sites	45	65.2
	>5 sites	24	34.8
Number of therapies before ICIs	Mean	4.4 therapies
	Q1, Q3	1, 6
	Range	0-16

NOS, not otherwise specified.